8-K Announcements
6Mar 23, 2026·SEC
Mar 6, 2026·SEC
Mar 2, 2026·SEC
Core Scientific, Inc. (CORZ) fundamental analysis — strengths, weaknesses & financial health based on data analysis
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Core Scientific, Inc. (CORZ) stock price & volume — 10-year historical chart
Core Scientific, Inc. (CORZ) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Core Scientific, Inc. (CORZ) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 2, 2026 | $0.29vs $0.27-7.4% | $80Mvs $119M-33.0% |
| Q4 2025 | Oct 24, 2025 | $0.46vs $0.07-558.9% | $81Mvs $112M-27.6% |
| Q3 2025 | Aug 8, 2025 | $0.04vs $0.07+42.9% | $79Mvs $111M-29.4% |
| Q2 2025 | May 7, 2025 | $0.10vs $0.12+16.7% | $80Mvs $85M-6.6% |
Core Scientific, Inc. (CORZ) competitors in Cloud infrastructure and hosting — business model, growth, and fundamentals comparison
Core Scientific, Inc. (CORZ) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Core Scientific, Inc. (CORZ) annual income statement — 10-year revenue, gross profit & net income history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 59.52M | 60.32M | 544.48M | 640.31M | 502.4M | 510.67M | 319.02M |
| Revenue Growth % | - | 1.34% | 802.66% | 17.6% | -21.54% | 1.65% | -37.53% |
| Cost of Goods Sold | 49M | 50.93M | 305.62M | 631.91M | 378.94M | 389.6M | 281.12M |
| COGS % of Revenue | 82.31% | 84.43% | 56.13% | 98.69% | 75.43% | 76.29% | 88.12% |
| Gross Profit | 10.53M▲ 0% | 9.39M▼ 10.8% | 238.86M▲ 2443.2% | 8.4M▼ 96.5% | 123.46M▲ 1369.8% | 121.07M▼ 1.9% | 37.9M▼ 68.7% |
| Gross Margin % | 17.69% | 15.57% | 43.87% | 1.31% | 24.57% | 23.71% | 11.88% |
| Gross Profit Growth % | - | -10.78% | 2443.25% | -96.48% | 1369.75% | -1.94% | -68.7% |
| Operating Expenses | 23.02M | 15.72M | 72.22M | 2.12B | 114.5M | 140.27M | 182.6M |
| OpEx % of Revenue | 38.67% | 26.06% | 13.26% | 330.77% | 22.79% | 27.47% | 57.24% |
| Selling, General & Admin | 17.54M | 16.32M | 64.55M | 226.01M | 100.93M | 120.42M | 182.6M |
| SG&A % of Revenue | 29.47% | 27.06% | 11.85% | 35.3% | 20.09% | 23.58% | 57.24% |
| Research & Development | 5.48M | 5.27M | 7.67M | 26.96M | 7.18M | 11.83M | 0 |
| R&D % of Revenue | 9.21% | 8.74% | 1.41% | 4.21% | 1.43% | 2.32% | - |
| Other Operating Expenses | 0 | -5.88M | 0 | 1.86B | 6.39M | 8.02M | 0 |
| Operating Income | -11.69M▲ 0% | -6.33M▲ 45.9% | 166.64M▲ 2733.8% | -2.11B▼ 1365.9% | 8.96M▲ 100.4% | -19.2M▼ 314.2% | -144.7M▼ 653.8% |
| Operating Margin % | -19.63% | -10.49% | 30.61% | -329.46% | 1.78% | -3.76% | -45.36% |
| Operating Income Growth % | - | 45.86% | 2733.79% | -1365.93% | 100.42% | -314.22% | -653.79% |
| EBITDA | -5.57M | 3.08M | 200M | -1.88B | 105.41M | 100.92M | -75.78M |
| EBITDA Margin % | -9.36% | 5.1% | 36.73% | -294.15% | 20.98% | 19.76% | -23.76% |
| EBITDA Growth % | - | 155.23% | 6402.02% | -1041.72% | 105.6% | -4.25% | -175.09% |
| D&A (Non-Cash Add-back) | 6.12M | 9.4M | 33.36M | 226.09M | 96.44M | 120.12M | 68.91M |
| EBIT | -11.69M | -7.77M | 107.43M | -2.07B | -159.57M | -1.28B | -144.7M |
| Net Interest Income | -235K | -4.44M | -44.35M | -96.83M | -86.24M | -37.07M | -3.28M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 235K | 4.44M | 44.35M | 96.83M | 86.24M | 37.07M | 3.28M |
| Other Income/Expense | -235K | -5.88M | -103.56M | -53.86M | -254.76M | -1.29B | -143.34M |
| Pretax Income | -11.92M▲ 0% | -12.21M▼ 2.4% | 63.08M▲ 616.8% | -2.16B▼ 3529.9% | -245.8M▲ 88.6% | -1.31B▼ 434.6% | -288.03M▲ 78.1% |
| Pretax Margin % | -20.03% | -20.24% | 11.58% | -337.87% | -48.93% | -257.34% | -90.29% |
| Income Tax | 0 | 0 | 15.76M | -17.09M | 683K | 859K | 583K |
| Effective Tax Rate % | 0% | 0% | 24.99% | 0.79% | -0.28% | -0.07% | -0.2% |
| Net Income | -11.92M▲ 0% | -12.21M▼ 2.4% | 47.31M▲ 487.6% | -2.15B▼ 4636.5% | -246.49M▲ 88.5% | -1.32B▼ 433.5% | -288.62M▲ 78.1% |
| Net Margin % | -20.03% | -20.24% | 8.69% | -335.2% | -49.06% | -257.5% | -90.47% |
| Net Income Growth % | - | -2.38% | 487.61% | -4636.52% | 88.52% | -433.5% | 78.05% |
| Net Income (Continuing) | -11.92M | -12.21M | 47.31M | -2.15B | -246.49M | -1.32B | -288.62M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.28▲ 0% | -0.06▲ 78.7% | 0.20▲ 435.0% | -6.30▼ 3250.0% | -0.65▲ 89.7% | -5.14▼ 690.8% | -0.88▲ 82.9% |
| EPS Growth % | - | 78.68% | 435.01% | -3250% | 89.68% | -690.77% | 82.88% |
| EPS (Basic) | -0.28 | -0.06 | 0.23 | -6.30 | -0.65 | -5.14 | -0.88 |
| Diluted Shares Outstanding | 379.86M | 379.86M | 233.31M | 340.65M | 379.86M | 255.83M | 318.07M |
| Basic Shares Outstanding | 379.86M | 379.86M | 207.26M | 340.65M | 379.86M | 255.83M | 318.07M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
Core Scientific, Inc. (CORZ) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 11.05M | 70.92M | 756.56M | 85.1M | 97.02M | 903.96M | 895.54M |
| Cash & Short-Term Investments | 6.66M | 8.67M | 117.87M | 15.88M | 50.41M | 836.2M | 311.38M |
| Cash Only | 6.66M | 8.67M | 117.87M | 15.88M | 50.41M | 836.2M | 311.38M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 287K | 1.11M | 1.68M | 3.54M | 7.16M | 1.02M | 0 |
| Days Sales Outstanding | 1.76 | 6.7 | 1.13 | 2.02 | 5.2 | 0.73 | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 1.41M | 59.93M | 250.35M | 37.38M | 24.59M | 66.74M | 584.16M |
| Total Non-Current Assets | 150.96M | 154.66M | 1.68B | 722.58M | 615.14M | 694.85M | 1.45B |
| Property, Plant & Equipment | 81.3M | 85.24M | 599.76M | 711.56M | 593.27M | 670.81M | 1.4B |
| Fixed Asset Turnover | 0.73x | 0.71x | 0.91x | 0.90x | 0.85x | 0.76x | 0.23x |
| Goodwill | 58.24M | 58.24M | 1.06B | 0 | 0 | 0 | 0 |
| Intangible Assets | 3.98M | 6.67M | 8.2M | 1.7M | 2.25M | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 7.45M | 4.5M | 18.59M | 9.32M | 19.62M | 24.04M | 50.32M |
| Total Assets | 162.01M▲ 0% | 225.58M▲ 39.2% | 2.44B▲ 981.2% | 807.69M▼ 66.9% | 712.16M▼ 11.8% | 1.6B▲ 124.5% | 2.35B▲ 46.8% |
| Asset Turnover | 0.37x | 0.27x | 0.22x | 0.79x | 0.71x | 0.32x | 0.14x |
| Asset Growth % | - | 39.23% | 981.17% | -66.88% | -11.83% | 124.5% | 46.84% |
| Total Current Liabilities | 19.47M | 69.65M | 320.29M | 186.79M | 488.42M | 134.56M | 781.4M |
| Accounts Payable | 7.5M | 3.06M | 11.62M | 53.64M | 154.75M | 19.27M | 126.11M |
| Days Payables Outstanding | 55.89 | 21.91 | 13.87 | 30.98 | 149.06 | 18.05 | 163.73 |
| Short-Term Debt | 648K | 16.02M | 76M | 36.24M | 124.36M | 16.29M | 0 |
| Deferred Revenue (Current) | 0 | 0 | 141.93M | 78.19M | 9.83M | 18.13M | 127.56M |
| Other Current Liabilities | 8.69M | 47.49M | 4.39M | 1.64M | 6.78M | 69.23M | 527.73M |
| Current Ratio | 0.57x | 1.02x | 2.36x | 0.46x | 0.20x | 6.72x | 1.15x |
| Quick Ratio | 0.57x | 1.02x | 2.36x | 0.46x | 0.20x | 6.72x | 1.15x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 6.69M | 22.23M | 777.37M | 1.03B | 820.67M | 2.28B | 2.53B |
| Long-Term Debt | 2.09M | 19.86M | 652.21M | 0 | 684.08M | 1.07B | 1.06B |
| Capital Lease Obligations | 3.18M | 2.26M | 62.15M | 720K | 37.26M | 97.85M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1.41M | 103K | 63.01M | 1.03B | 99.33M | 1.11B | 1.47B |
| Total Liabilities | 26.16M | 91.88M | 1.1B | 1.22B | 1.31B | 2.42B | 3.31B |
| Total Debt | 7.49M | 40.29M | 818.81M | 37.73M | 865.54M | 1.2B | 1.06B |
| Net Debt | 837K | 31.62M | 700.93M | 21.85M | 815.14M | 363.57M | 748.95M |
| Debt / Equity | 0.06x | 0.30x | 0.61x | - | - | - | - |
| Debt / EBITDA | - | 13.10x | 4.09x | - | 8.21x | 11.89x | - |
| Net Debt / EBITDA | - | 10.28x | 3.50x | - | 7.73x | 3.60x | - |
| Interest Coverage | -49.73x | -1.43x | 3.76x | -21.79x | 0.10x | -0.52x | -44.16x |
| Total Equity | 135.85M▲ 0% | 133.7M▼ 1.6% | 1.34B▲ 903.1% | -409.35M▼ 130.5% | -596.94M▼ 45.8% | -820.18M▼ 37.4% | -962.74M▼ 17.4% |
| Equity Growth % | - | -1.59% | 903.15% | -130.52% | -45.83% | -37.4% | -17.38% |
| Book Value per Share | 0.36 | 0.35 | 5.75 | -1.20 | -1.57 | -3.21 | -3.03 |
| Total Shareholders' Equity | 135.85M | 133.7M | 1.34B | -409.35M | -596.94M | -820.18M | -962.74M |
| Common Stock | 1K | 1K | 27K | 36K | 36K | 3K | 3K |
| Retained Earnings | -62.54M | -74.74M | -27.43M | -2.17B | -2.42B | -3.74B | -4.15B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | -10.97M | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Core Scientific, Inc. (CORZ) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -832K | -23.77M | -56.73M | 205.19M | 65.11M | 42.9M | 278.25M |
| Operating CF Margin % | -1.4% | -39.4% | -10.42% | 32.04% | 12.96% | 8.4% | 87.22% |
| Operating CF Growth % | - | -2756.37% | -138.73% | 461.66% | -68.27% | -34.12% | 548.66% |
| Net Income | -11.92M | -12.21M | 47.31M | -2.15B | -246.49M | -1.32B | -288.62M |
| Depreciation & Amortization | 6.12M | 9.4M | 33.36M | 226.09M | 96.44M | 120.12M | 68.91M |
| Stock-Based Compensation | 2.88M | 3.04M | 38.94M | 182.89M | 58.89M | 51.92M | 98.24M |
| Deferred Taxes | 0 | 0 | 9.53M | -18.52M | 0 | 0 | 0 |
| Other Non-Cash Items | -3.59M | -2.87M | -136.36M | 1.88B | -394.77M | 1.21B | 399.72M |
| Working Capital Changes | 5.68M | -21.13M | -49.52M | 78.61M | 551.03M | -27.64M | 0 |
| Change in Receivables | -83K | -1.55M | -7.41M | -7.58M | -744K | 659K | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | -1.77M | -21.99M | 26.71M | 118.6M | -12.27M | 10.78M |
| Cash from Investing | -37.36M | -15.14M | -423.84M | -590.78M | -3M | -95.19M | -740.75M |
| Capital Expenditures | -37.41M | -1.57M | -59.27M | -601.66M | -16.16M | -94.96M | -729M |
| CapEx % of Revenue | 62.85% | 2.6% | 10.89% | 93.96% | 3.22% | 18.6% | 228.51% |
| Acquisitions | 0 | -13.67M | -365.21M | 10.85M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 52K | 92K | 645K | -10.82M | 13.16M | -231K | -6.75M |
| Cash from Financing | 28.69M | 40.72M | 603.53M | 306.15M | -44.65M | 819.57M | -63.1M |
| Debt Issued (Net) | -832K | 38.08M | 613.7M | 117.74M | -40.99M | 766.91M | 0 |
| Equity Issued (Net) | 0 | 0 | 1000K | -1000K | 0 | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | -31.65M | 0 | 0 | 0 |
| Other Financing | 29.53M | 2.64M | -681.43M | 220.06M | -3.66M | -2.34M | -63.1M |
| Net Change in Cash | -9.5M▲ 0% | 1.81M▲ 119.1% | 122.96M▲ 6678.2% | -79.44M▼ 164.6% | 17.47M▲ 122.0% | 767.27M▲ 4292.2% | -525.6M▼ 168.5% |
| Free Cash Flow | -38.24M▲ 0% | -25.33M▲ 33.8% | -116.01M▼ 357.9% | -396.47M▼ 241.8% | 48.95M▲ 112.3% | -52.06M▼ 206.4% | -450.75M▼ 765.7% |
| FCF Margin % | -64.25% | -42% | -21.31% | -61.92% | 9.74% | -10.2% | -141.29% |
| FCF Growth % | - | 33.76% | -357.94% | -241.75% | 112.35% | -206.36% | -765.74% |
| FCF per Share | -0.10 | -0.07 | -0.50 | -1.16 | 0.13 | -0.20 | -1.42 |
| FCF Conversion (FCF/Net Income) | 0.07x | 1.95x | -1.20x | -0.10x | -0.26x | -0.03x | -0.96x |
| Interest Paid | 0 | 2.9M | 38.18M | 86.01M | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 9.62M | 5.76M | 0 | 0 | 0 |
Core Scientific, Inc. (CORZ) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -8.78% | -9.06% | 6.42% | -460.65% | - | - | - |
| Return on Invested Capital (ROIC) | - | -3.14% | 11.32% | -191.24% | 3.08% | - | - |
| Gross Margin | 17.69% | 15.57% | 43.87% | 1.31% | 24.57% | 23.71% | 11.88% |
| Net Margin | -20.03% | -20.24% | 8.69% | -335.2% | -49.06% | -257.5% | -90.47% |
| Debt / Equity | 0.06x | 0.30x | 0.61x | - | - | - | - |
| Interest Coverage | -49.73x | -1.43x | 3.76x | -21.79x | 0.10x | -0.52x | -44.16x |
| FCF Conversion | 0.07x | 1.95x | -1.20x | -0.10x | -0.26x | -0.03x | -0.96x |
| Revenue Growth | - | 1.34% | 802.66% | 17.6% | -21.54% | 1.65% | -37.53% |
Core Scientific, Inc. (CORZ) SEC filings — annual & quarterly reports (10-K, 10-Q)
Mar 23, 2026·SEC
Mar 6, 2026·SEC
Mar 2, 2026·SEC
Core Scientific, Inc. (CORZ) stock FAQ — growth, dividends, profitability & financials explained
Core Scientific, Inc. (CORZ) reported $319.0M in revenue for fiscal year 2025. This represents a 436% increase from $59.5M in 2019.
Core Scientific, Inc. (CORZ) saw revenue decline by 37.5% over the past year.
Core Scientific, Inc. (CORZ) reported a net loss of $288.6M for fiscal year 2025.
Core Scientific, Inc. (CORZ) had negative free cash flow of $460.9M in fiscal year 2025, likely due to heavy capital investments.
Core Scientific, Inc. (CORZ) financial analysis — history, returns, DCA and operating performance tools
Historical returns with dividends reinvested
Dollar cost averaging vs lump sum
Yield, growth, payout safety & DRIP
EPS trends, net income & profitability
Long-term charts & historical price data
Sales growth patterns & revenue breakdown
30 years of market, efficiency and balance-sheet ratios
DCF intrinsic value, peer multiples & estimates